Alzheimer’s disease is a neurodegenerative disease and is characterized by cognitive decline and memory loss. Difficulties in maintaining daily living activities with disease progression are defined as functional disability. Functional disability, which is considered an important factor for quality of life in Alzheimer’s disease, is associated with the disease stage. Functional disability in Alzheimer’s disease is characterized by difficulties in complex activities in the early stages of the disease, while it is characterized by difficulties in basic activities of daily living in the advanced stages of the disease. Amyloid-beta plaques, neurofibrillary tangles such as tau proteins, synaptic dysfunction, and neuroinflammatory factors play an important role in the pathogenesis of functional disability in this disease. Matrix metalloproteinases (MMPs) are a family of enzymes important in extracellular matrix degradation, which may have complex effects in the pathogenesis of Alzheimer’s disease. The MMP enzyme system plays an important role in normal physiological processes in the nervous system. In addition, this enzyme system is also effective in pathological conditions such as amyloid-beta metabolism, blood-brain barrier integrity disruption, neuroinflammation, synaptic dysfunction, and neuronal loss. The significant relationship has been reported between functional disability progression in Alzheimer’s disease and imbalances in the MMP system. As a result of imbalances in MMP activity, pathological processes are triggered and functional capacity deteriorates rapidly. Modulating the MMP system through MMP activators or inhibitors may enable the development of new therapeutic strategies aimed at slowing down functional disability in Alzheimer’s disease. By better understanding the role of the MMP system in functional disability in Alzheimer’s disease, it may be possible to develop therapeutic approaches that can stop or slow down the disease.